Lazar Dimitrov is a Principal in the Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December of 2018.
Dr. Dimitrov is focused on investments across the firm's portfolio, including startups and partnerships with pharmaceutical companies Dr. Dimitrov joined Clarus in August 2015 with a diverse business and scientific background. His business experience spans investment banking (Merrill Lynch), venture capital (Rho Ventures), internet and biotechnology start-ups (Priceline WebHouse Club, Crystal Bioscience) and management consulting (Blue Matter Consulting). Dr. Dimitrov is currently a board observer for Graybug Vision, SFJ Pharmaceuticals, Galera Therapeutics and Lumos Pharma.
Dr. Dimitrov obtained his PhD in Genome Sciences from the University of Washington studying mitochondrial biology and aging in the lab of Dr. Dan Gottschling at the Fred Hutchinson Cancer Research Center. He conducted his postdoctoral training in genetics, biochemistry and cell biology at U.C. Berkeley in the lab of Randy Schekman, 2013 Nobel Prize winner in Physiology and Medicine. Dr. Dimitrov received his BA in Mathematics and Economics with high honors from Dartmouth College.